4.4 Article

Valnoctamide, a non-teratogenic amide derivative of valproic acid, inhibits arachidonic acid activation in vitro by recombinant acyl-CoA synthetase-4

期刊

BIPOLAR DISORDERS
卷 16, 期 8, 页码 875-880

出版社

WILEY
DOI: 10.1111/bdi.12220

关键词

acyl-CoA synthetase 4; anticonvulsant; arachidonic acid; bipolar disorder; brain; cascade; enzyme; inhibition; metabolism; Michaelis-Menten kinetics; mood stabilizer; rat; valnoctamide; valproate

资金

  1. Intramural Research Program of the National Institute on Aging, National Institute of Health

向作者/读者索取更多资源

ObjectiveValproic acid (VPA), a mood stabilizer used for treating bipolar disorder (BD), uncompetitively inhibits acylation of arachidonic acid (AA) by recombinant AA-selective acyl-CoA synthetase 4 (Acsl4) at an enzyme inhibition constant (K-i) of 25mM. Inhibition may account for VPA's ability to reduce AA turnover in brain phospholipids of unanesthetized rats and to be therapeutic in BD. However, VPA is teratogenic. We tested whether valnoctamide (VCD), a non-teratogenic amide derivative of a VPA chiral isomer, which had antimanic potency in a phase III BD trial, also inhibits recombinant Acsl4. MethodsRat Acsl4-flag protein was expressed in Escherichia coli. We used Michaelis-Menten kinetics to characterize and quantify the ability of VCD to inhibit conversion of AA to AA-CoA by recombinant Acsl4 in vitro. ResultsAcsl4-mediated activation of AA to AA-CoA by Acsl4 was inhibited uncompetitively by VCD, with a K-i of 6.38mM. ConclusionsVCD's ability to uncompetitively inhibit AA activation to AA-CoA by Acsl4, at a lower K-i than VPA, suggests that, like VPA, VCD may reduce AA turnover in rat brain phospholipids. If so, VCD and other non-teratogenic Acsl4 inhibitors might be considered further for treating BD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据